Australia markets closed

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
40.50+0.40 (+1.00%)
At close: 04:00PM EDT
40.50 0.00 (0.00%)
After hours: 04:20PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 3.02B
Enterprise value 2.40B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.26
Enterprise value/revenue 10.87k
Enterprise value/EBITDA -11.39

Trading information

Stock price history

Beta (5Y monthly) 1.18
52-week change 31.30%
S&P500 52-week change 322.36%
52-week high 350.99
52-week low 327.99
50-day moving average 344.07
200-day moving average 339.72

Share statistics

Avg vol (3-month) 3361.51k
Avg vol (10-day) 3347.29k
Shares outstanding 575.43M
Implied shares outstanding 675.43M
Float 869.56M
% held by insiders 10.38%
% held by institutions 1100.09%
Shares short (15 Apr 2024) 42.62M
Short ratio (15 Apr 2024) 48.59
Short % of float (15 Apr 2024) 43.48%
Short % of shares outstanding (15 Apr 2024) 43.47%
Shares short (prior month 15 Mar 2024) 42.62M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-15.57%
Return on equity (ttm)-22.12%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -210.51M
Net income avi to common (ttm)-182.39M
Diluted EPS (ttm)-2.73
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)638.08M
Total cash per share (mrq)8.46
Total debt (mrq)10.9M
Total debt/equity (mrq)1.17%
Current ratio (mrq)23.65
Book value per share (mrq)12.31

Cash flow statement

Operating cash flow (ttm)-145.33M
Levered free cash flow (ttm)-98.4M